Press Releases
Latest News & Events
12/03/2021
Disruptive Applications in Oncology and Beyond
23/12/2020
Seven severely ill patients treated with Enlivex’s Allocetra, have fully recovered.
05/11/2020
The Staging of a New Disease and Its Implications for Treatment Options
01/10/2020
All five in serious or critical condition before being treated with Allocetra
16/02/2020
The innovative therapy is based on the research of Prof. Dror Mevorach
Investment Highlights
Macrophage reprogramming, unmet medical need indications
Off-the-shelf, universal cell therapy for resetting macrophages back to their ”manufacturer settings”, and away from “disease settings”
Advanced clinical-stage pipeline
Phase IIb macrophage reprogramming for sepsis; Phase II COVID-19 Phase Ib macrophage reprogramming for solid tumor scheduled for 2021
Short regulatory approval pathway
Specialized regulation in Europe potentially enabling post-Phase II marketing approval in sepsis and COVID-19
Multi-billion dollar underserved markets
Sepsis | Solid Tumors | COVID-19 | ARDS
Strong leadership
Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment
Cash balance
~$60 million invested; Cash balance supporting multiple clinical milestones within 18-24 months; Funded through Q1 2023
SEC Filings
Date Form Description Download
Corporate Governance
Charter of the Audit Committee of the Board of Directors download
Charter of the Compensation Committee of the Board of Directors download
Code of Business Conduct and Ethics download
Disclosure Policy download
Employee Complaint Procedures for Accounting and Auditing Matters download
Insider Trading Policy download
Subscribe to our newsletter
Find out more
14 Einstein St. Nes-Ziona, Israel, 7403618
T +972.2.6708072 | F +972.2.6708070
info@enlivex.com